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S U M M A R Y
Background: The lack of Treponema pallidum-speciﬁc antigens with highly accurate diagnosis makes the
diagnosis of syphilis challenging.
Methods: A soluble recombinant version of a new diagnostic protein Tp0663 has been produced. The
serodiagnostic potential of this protein was assessed by screening 3326 serum samples simultaneously
evaluated by rapid plasma reagin and T. pallidum particle agglutination tests. Kappa (k) coefﬁcients were
used to compare the concordance between clinical diagnosis and the Tp0663-based ELISA or the
ARCHITECT Syphilis TP chemiluminescent immunoassay (Abbott GmbH and Co. KG).
Results: Using the results of clinical diagnosis as the gold standard, the sensitivity and speciﬁcity of
Tp0663 were found to be 98.83% (95% conﬁdence interval (CI) 96.61–99.60%) and 100% (95% CI 99.88–
100%), respectively. In comparison, the ARCHITECT Syphilis TP assay was found to have a lower
sensitivity (97.27%, 95% CI 94.46–98.67%) and speciﬁcity (99.61%, 95% CI 99.32–99.78%). In particular,
the ARCHITECT Syphilis TP exhibited a false-positive rate of 0.39%. Moreover, the ELISA was in perfect
agreement with the gold standard, with a k value of 0.99, comparable to that of ARCHITECT Syphilis TP
(0.96).
Conclusion: These results identiﬁed Tp0663 as a novel serodiagnostic candidate with great potential for
developing novel tests for the diagnosis of syphilis.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Syphilis is a perplexing infection caused by the spirochete
Treponema pallidum, which is transmitted primarily through
sexual contact. It progresses through multiple clinical stages, with
typical clinical features including the hard chancre during primary§ This work was performed at the Institution of Pathogenic Biology, Medical
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).syphilis, followed by a generalized rash and lymphadenopathy
during secondary syphilis. Upon resolution of this stage of syphilis,
the infection enters an asymptomatic, latent phase lasting from
months to decades. Diverse and chronic symptoms emerge during
tertiary syphilis, including neurosyphilis, cardiovascular involve-
ment, and gummas.1
The laboratory diagnosis of syphilis is dependent on the use of a
multitude of serological tests due to the fact that T. pallidum cannot
be cultured in vitro;2,3 this is in contrast to most bacterial diseases,
for which a deﬁnite diagnosis can be made by direct detection of
the pathogen. The common serological tests for the diagnosis of
syphilis are divided into two categories: non-treponemal tests and
treponemal tests. The non-treponemal tests, such as the rapid
plasma reagin (RPR) test and the venereal disease research
laboratory (VDRL) test, are used mainly to determine serologicalciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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advantages of these tests, which are widely available, inexpensive,
and simple to perform, the results require further conﬁrmatory
screening for the detection of Treponema-speciﬁc antibodies. The
treponemal tests, such as the T. pallidum particle agglutination
(TPPA) assay, the T. pallidum hemagglutination (TPHA) assay, and
the ﬂuorescent treponemal antibody absorption (FTA-ABS) test,
are used to detect the speciﬁc treponemal antibodies. Neverthe-
less, these tests are labor-intensive and highly operator-depen-
dent. Furthermore, they exhibit poor sensitivities in the detection
of early syphilis.4
In recent years, automated enzyme immunoassays (EIAs) and
chemiluminescence immunoassays (CIAs) have also been devel-
oped for the serodiagnosis of syphilis. These assays, using one or
more of the recombinant T. pallidum proteins TpN15 (Tp0171),
TpN17 (Tp0435), TpN44.5 (TmpA, Tp0768), and TpN47
(Tp0574),5,6 have gained the interest of researchers in the ﬁeld
of syphilis diagnosis because they are objective, reproducible,
automated, and computerized.7 More importantly, these tests
have led some large laboratories in the USA to screen patients
with the reverse algorithm, which begins with a treponemal test;
reactive tests are followed by a quantitative non-treponemal test
and discordant samples must be rescreened with a second and
different treponemal test.8,9 Although these proteins have been
used in the serodiagnosis of syphilis, there is no general
agreement as to which protein antigens are best in terms of
serodiagnostic performance, and surface-exposed proteins may
have superior sensitivity to the currently used proteins due to
their immediate exposure to the immune system. Therefore, it is
of great importance to evaluate new recombinant antigens with
highly accurate diagnosis for use in serological testing for
syphilis.
The purpose of this study was to analyze the diagnostic
potential of recombinant antigen Tp0663, a 28-kDa T. pallidum
subsp. pallidum outer membrane protein that has previously been
reported in several works as being reactive with sera from syphilis
patients.10,11 The sensitivity and speciﬁcity of the recombinant
antigen were evaluated using sera collected from 3326 individuals,
and subsequently compared with the recently launched ARCHI-
TECT Syphilis TP test, a CIA that exhibits excellent ability to
automate testing in high-throughput instrumentations. The results
showed that the T. pallidum protein Tp0663-based immunoglobu-
lin G (IgG) ELISA exhibited higher overall sensitivity and speciﬁcity
than the ARCHITECT Syphilis TP. Therefore, Tp0663 represents a
promising new candidate that could potentially be incorporated
into automated diagnostic tests for syphilis.
2. Materials and methods
2.1. Genomic DNA of Treponema pallidum subsp. pallidum Nichols
strain
The T. pallidum subsp. pallidum Nichols strain used in this
study was a generous gift from Tianci Yang (Zhongshan Hospital,
Medical College of Xiamen University, Xiamen, China) and was
propagated in adult New Zealand white rabbits, as described
elsewhere.12,13 All animal experiments were approved by the
Institutional Review Committee of the University of South
China.
2.2. Serum samples
This study was approved by the Human Ethics Committee of the
University of South China and was performed in compliance with
the Declaration of Helsinki guidelines and national legislation.
Informed consent was obtained from all participants. Humanserum samples were collected from The First Afﬁliated Hospital,
University of South China (Hengyang, China), The Second Afﬁliated
Hospital, University of South China (Hengyang, China), The First
People’s Hospital of Changde (Changde, China), and Hunan
Provincial People’s Hospital (Changsha, China) between February
2015 and May 2015. The serological detection of syphilis in each
sample (from 3326 subjects) was performed using the RPR and
TPPA tests, which were performed in accordance with the
manufacturers’ instructions, after duplicate tests were excluded.
All serological tests were performed on the same serum sample,
and the results of the two tests were reported simultaneously. The
subjects in this study included 948 individuals undergoing routine
health examinations, 1358 outpatients, and 1020 inpatients.
These subjects underwent syphilis detection for screening (if
asymptomatic), for diagnosis (if symptomatic), or to monitor the
effects of therapy. In accordance with the staging criteria
described in the literature,14 the clinical diagnosis of syphilis
was determined by combining serological tests and disease
history (including clinical signs and symptoms, and/or the
patient’s sexual history). Primary syphilis is generally character-
ized by painless chancre and serous ﬂuids from the lesion, usually
coupled with regional lymphadenopathy; there has generally
been sexual contact with a person with syphilis, and laboratory
conﬁrmation involves dark-ﬁeld examination and/or positive
results of both RPR and TPPA to conﬁrm the diagnosis of syphilis.
Secondary syphilis is often characterized by a generalized rash,
mucocutaneous lesions, and lymphadenopathy; there is generally
a history of sexual exposure to a person with syphilis or primary
syphilis, and reactive serological tests (RPR and TPPA) are used to
conﬁrm the diagnosis. Latent syphilis is asymptomatic, with a
possible history of infection supported by a reactive RPR or TPPA
result. An onset of infection within the last 2 years is referred to as
early latent syphilis and a duration of latent syphilis >2 years is
deﬁned as late latent syphilis. Tertiary syphilis is considered as
syphilis presenting with typical clinical symptoms, such as
gummatous lesions, neuropsychiatric illness, and cardiovascular
involvement, and a history of primary, secondary, or latent
syphilis, in addition to clinical conﬁrmation by positive results of
both RPR and TPPA. The diagnostic tests used to conﬁrm the serum
samples are listed in Table 1.
2.3. Recombinant protein expression and puriﬁcation
The tp0663 gene was ampliﬁed by PCR using the forward primer
50-CCGGAATTCATGAAACAGGGCTGTTTTAT 30 (EcoRI) and the
reverse primer 50-CCCAAGCTTTCATTTGCCGCTCTCTCCTT 30 (Hin-
dIII) and then cloned into pET-28a expression vector. This
construct was transformed into Escherichia coli BL21 (DE3) cells
and the positive clone was conﬁrmed by DNA sequencing. Protein
expression was induced overnight at 30 8C with 0.1 mM isopropyl-
b-D-thiogalactopyranoside (IPTG). Bacteria were harvested and
lysed in a buffer containing 50 mM Tris–HCl (pH 7.8), 300 mM
NaCl, 10 mM imidazole, 20% glycerol, and 1% Triton X-100. His-
tagged protein was puriﬁed by afﬁnity chromatography using Ni-
NTA beads (Qiagen, Inc., Hilden, Germany). The concentration of
the recombinant protein was estimated using a bicinchoninic acid
protein assay kit (Pierce, Rockford, USA).
2.4. Western blotting analysis
Recombinant protein Tp0663 was electrophoresed in a 12%
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) gel and then transferred to a nitrocellulose membrane
(Merck Millipore, Darmstadt, Germany). After blocking at room
temperature for 2 h with phosphate-buffered saline (PBS)
containing 5% nonfat milk and 0.05% Tween 20 (PBSTM),
Table 1
Serological tests used to conﬁrm the characterized serum samples (N = 3326)
Bacterium/virus Serological test Manufacturer
Treponema pallidum Rapid plasma reagin test KeHua Bio-Engineering Inc., Shanghai, China
Treponema pallidum T. pallidum particle agglutination test Fujirebio, Tokyo, Japan
Hepatitis B virus Total anti-HBs or anti-HBc test Abbott, Chicago, USA
Hepatitis C virus HCV test Abbott, Chicago, USA
Helicobacter pylori H. pylori IgG test Abbott, Chicago, USA
Cytomegalovirus Architect cytomegalovirus IgG test Abbott, Chicago, USA
HBs, hepatitis B surface antigen; HBc, hepatitis B core antigen; HCV, hepatitis C virus.
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(1:500), rabbit sera (1:400), or anti-His-tagged monoclonal
antibody (1:1000). Before being incubated separately with
corresponding secondary antibodies at 37 8C for 1 h, membranes
were washed extensively with PBS containing 0.05% Tween 20
(PBST) (the dilutions of secondary antibodies were as follows:
horseradish peroxidase (HRP)-conjugated goat anti-human IgG
(Abcam, Cambridgeshire, UK), 1:8000; HRP-conjugated goat anti-
rabbit IgG (Abcam), 1:12 000; HRP-conjugated goat anti-mouse
IgG (Millipore, Darmstadt, Germany), 1:10 000). Finally, chemi-
luminescent detection was performed using G:BOX Chemi XXX9
(Syngene, Cambridge, UK) after washing ﬁve times with PBST.
2.5. ELISA
Recombinant protein Tp0663 was diluted in carbonate buffer
(0.1 M, pH 9.6), then 96-well plates (Corning Costar, New York,
USA) were coated with 100 ml per well overnight at 4 8C. With
intervening washes, the plates were blocked for 2 h at room
temperature with 200 ml PBSTM. Serum samples were diluted
1:100 with PBSTM, and 100 ml was added to each well. After
incubation for 2 h at 37 8C, the plates were washed extensively
with PBST. HRP-conjugated goat anti-human IgG was used at a
dilution of 1:10 000, and then 100 ml was added to each well. The
mixture was incubated for 1 h at 37 8C. Plates were developed by
adding 100 ml tetramethylbenzidine substrate to each well and
incubated at room temperature for 30 min. The reaction was
stopped by the addition of 100 ml of 1 M sulfuric acid. The
absorbance was read at 450 nm. Each sample was assayed in
duplicate. The mean optical density value for the uninfected
control sera determined by clinical diagnosis plus two times the
standard deviation was considered as the cutoff value to determine
positivity in each sample. The cutoff value of the ELISA was
0.4121. Absorbance values less than or equal to the cutoff value
were determined to be negative, while those greater than the
cutoff value were deﬁned as positive.
2.6. ARCHITECT Syphilis TP
ARCHITECT Syphilis TP is a two-step immunoassay performed
on an fully automated system Architect i2000SR analyzer (Abbott,
Chicago, USA), which utilizes recombinant treponemal antigens
(TpN15, TpN17, and TpN47) to qualitatively detect the IgG and IgM
antibodies to T. pallidum in human serum or plasma. This test has
shown perfect performance when compared to the TPPA15 and
could be used as a reliable test for the detection of syphilis.16,17 The
results of the chemiluminescent reaction are measured in relative
light units (RLUs), with an RLU value of <1.00 indicating a negative
result and an RLU value of 1.00 indicating a positive result. The
level of RLUs is directly related to the amount of anti-T. pallidum
antibodies in the serum. All serum samples described above,
including positives from different stages of infection and
nonreactive samples, were screened in duplicate according to
the manufacturer’s instructions.2.7. Statistical analysis
SPSS software version 18.0 (SPSS Inc., Chicago, IL, USA) was used
for the statistical analysis of the data. The diagnostic performances
of the two serological tests were evaluated by contrasting them
with the gold standard, namely, the combination of the serological
tests, imaging diagnosis, and histological examination. The
percentages of agreement and kappa (k) coefﬁcients were also
calculated to analyze the agreement between clinical diagnosis
and the ELISA or ARCHITECT Syphilis TP. The agreement of the
results by k values was considered near perfect (0.81–1.0),
substantial (0.61–0.8), moderate (0.41–0.6), fair (0.21–0.4), slight
(0–0.2), or poor (<0).18
3. Results
3.1. Clinical diagnosis of syphilis patients
In this study, RPR and TPPA tests were performed on samples
from 3326 subjects between February 2015 and May 2015. Syphilis
was diagnosed clinically by combining serodiagnosis and personal
history (including the patient’s sexual history and clinical
characteristics). Ultimately, 256 subjects were diagnosed with
syphilis and 632 subjects were found to be healthy by clinicians.
Thus, the prevalence of syphilis was 7.70% (256 of 3326 patients).
The clinical data for all of the subjects are given in Table 2.
3.2. Recombinant protein expression, puriﬁcation, and identiﬁcation
The tp0663 gene was successfully ampliﬁed by PCR (Figure 1).
The optimal expression of the His-tagged protein was observed
with induction of 0.1 mM IPTG overnight at 30 8C. The soluble
recombinant protein was determined through SDS-PAGE analysis
to have an estimated purity of >95% (Figure 2). The antigenicity of
Tp0663 was conﬁrmed using anti-His monoclonal antibody, rabbit
sera infected with T. pallidum Nichols strain (n = 2), and serum
samples from syphilis patients (n = 18) (Figure 3). These sera from
the syphilis patients, including two samples from patients with
primary syphilis, three from patients with secondary syphilis, two
from patients with early latent syphilis, seven from patients with
late latent syphilis, and four from patients with tertiary syphilis,
showed reactivity to recombinant protein Tp0663. However, no
reactivity between Tp0663 and normal human sera (n = 5) or
serum samples from patients infected with hepatitis B virus (n = 4),
hepatitis C virus (n = 1), Helicobacter pylori (n = 1), and cytomega-
lovirus (n = 1) was observed in this study (Figure 4). These ﬁndings
showed that the recombinant antigen exhibited 100% sensitivity
and 100% speciﬁcity in the Western blotting analysis.
3.3. Evaluation of the diagnostic performances of the two syphilis
serological tests compared with the gold standard
With the clinical diagnosis of syphilis as the gold standard, the
serodiagnostic potential of the two syphilis serological tests was
Table 2
Clinical data for the 3326 subjects evaluated
Characteristic No. (%)
(N = 3326)
Sex
Male 1929 (58.00%)
Female 1397 (42.00%)
Age, years 1–91 (mean 47.15)
Male 1–87 (mean 49.28)
Female 2–91 (mean 42.36)
Ethnicity
Han 3223 (96.90%)
Other 103 (3.10%)
Married
Yes 2295 (69.00%)
No 1031 (31.00%)
History of infection
Yes 166 (5.00%)
No 3160 (95.00%)
Reason for detection
Screening (asymptomatic subjects) 1397 (42.00%)
Health examination 948 (67.86%)
Subject request 155 (11.10%)
Hospitalization 223 (15.96%)
Other 71 (5.08%)
Diagnosis (symptomatic subjects) 1713 (51.50%)
Sexual exposure to suspected syphilis patient 31 (1.81%)
Chancre, rash, gumma, or neurological involvement 138 (8.06%)
Other 1544 (90.13%)
Monitoring of therapeutic effect 216 (6.50%)
Infection
Treponema pallidum 256 (7.70%)
Helicobacter pylori 17 (0.51%)
Cytomegalovirus 2 (0.06%)
Hepatitis B virus 9 (0.27%)
Hepatitis C virus 3 (0.09%)
Healthy 632 (19.00%)
Unknown 7 (0.21%)
Other 2400 (72.16%)
Clinical stages of syphilis 256 (7.70%)
Primary 11 (4.30%)
Secondary 35 (13.67%)
Tertiary 56 (21.88%)
Early latent 28 (10.94%)
Late latent 126 (49.22%)
Figure 1. PCR ampliﬁcation of the tp0663 gene. Lane 1, 100-bp DNA ladder; lane 2,
ampliﬁed product of the tp0663 gene.
Figure 3. Identiﬁcation of Treponema pallidum protein Tp0663. Western blotting
analysis of the immunoreactivity of recombinant protein Tp0663 with sera from
uninfected controls (C), anti-His monoclonal antibody (1), rabbit sera infected with
T. pallidum Nichols strain (2), and sera from syphilis patients (3).
Figure 2. SDS-PAGE analysis of recombinant protein Tp0663 puriﬁcation. Lane M,
pre-stained protein marker; lane 1, cleared lysate; lane 2, ﬂow through of the lysate;
lane 3, eluted fraction of recombinant protein Tp0663.
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ARCHITECT Syphilis TP, 261 of the 3326 subjects would have
been diagnosed with syphilis, whereas seven subjects deter-
mined to be syphilis patients by clinical diagnosis would not
have been diagnosed. Among these syphilis patients, 12 were
conﬁrmed to be healthy by clinical diagnosis. The false-positive
rate was 0.39% (12 of 3070 subjects) and the missed diagnosis
rate was 2.73% (7 of 256 subjects). Furthermore, the sensitivity of
the ARCHITECT Syphilis TP was 97.27% (95% conﬁdence interval
(CI) 94.46–98.67%) (Table 3). In addition, the seven cases of
missed diagnosis were analyzed further. It was found that there
was one case of primary syphilis, three of late latent syphilis, and
three of tertiary syphilis. Moreover, among these seven cases,
three patients were being diagnosed with syphilis for the ﬁrst
time.
In comparison, using the ARCHITECT Syphilis TP and the
Tp0663-based ELISA, 249 and 253 subjects, respectively, had a
reactive serodiagnosis. The sensitivity levels of the ARCHITECT
Syphilis TP and the ELISA were 97.27% (95% CI 94.46–98.67%) and
98.83% (95% CI 96.61–99.60%), respectively. In addition, the
speciﬁcities of the ARCHITECT Syphilis TP and the ELISA were
96.61% (95% CI 99.32–99.78%) and 100% (95% CI 99.88–100%),
respectively (Table 3). Both the ARCHITECT Syphilis TP and the
antigen exhibited strong discriminatory power in the serodiag-
nosis of syphilis.
Figure 4. Reactivities to recombinant protein Tp0663 of sera from patients at different stages of syphilis, individuals diagnosed with other diseases, and uninfected controls by
Western blotting analysis. Western blotting analysis of recombinant protein Tp0663 with serum samples from uninfected controls (C), patients with primary syphilis (1),
secondary syphilis (2), early latent syphilis (3), late latent syphilis (4), tertiary syphilis (5), hepatitis B virus (6), hepatitis C virus (7), cytomegalovirus (8), and human
immunodeﬁciency virus (9) using HRP-conjugated goat anti-human IgG.
Table 4
Comparison of the two serodiagnosis tests at different stages of syphilis
Diagnosis No. of serum
samples tested
No. (%) of serodiagnosis positive
ARCHITECT Syphilis TP Tp0663-based ELISA
Primary 11 10 (90.91) 11 (100)
Secondary 35 35 (100) 34 (97.14)
Early latent 28 28 (100) 28 (100)
Late latent 126 123 (97.62) 125 (99.21)
Tertiary 56 53 (94.64) 55 (98.21)
Total 256 249 (97.27) 253 (98.83)
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syphilis
The 256 cases of syphilis were further classiﬁed into different
stages of syphilis to evaluate the two serological tests at the
different stages (Table 4). It was found that the ARCHITECT Syphilis
TP had high sensitivity not only for primary syphilis (90.91%) and
secondary syphilis (100%), but also for tertiary syphilis (94.64%).
The ELISA exhibited sensitivities of 100%, 97.14%, and 98.21% for
primary, secondary, and tertiary syphilis, respectively.
3.5. Direct comparison of the concordance between clinical diagnosis
and the Treponema pallidum recombinant antigen Tp0663-based
ELISA or the ARCHITECT Syphilis TP
For all of the samples, the agreement and k values of the ELISA
and the ARCHITECT Syphilis TP were compared with clinical
diagnosis (gold standard). The ELISA showed 99.91% (95% CI 99.88–
99.94%) agreement and a k value of 0.99, and the ARCHITECT
Syphilis TP exhibited 99.43% (95% CI 99.36–99.50%) agreement and
a k value of 0.96 (Table 5). The results indicated that the two
serological tests had high consistency with clinical diagnosis.
4. Discussion
The identiﬁcation and characterization of new immunodomi-
nant antigens of T. pallidum is central to the improvement of the
current laboratory diagnosis of syphilis, a disease that has resurged
worldwide in recent years, including in China.19–21 A variety of T.
pallidum proteins, including TpN44.5, TpN15, TpN17, TpN47,
Tp0453, Tp92 (Tp0326), and TpF1 (Tp1038),5,6,22–24 have been
tested in recent decades. Some of these antigens have been used in
commercial tests that exhibit high sensitivity and speciﬁcity.
However, not all patients suffering from syphilis are detected with
the use of these antigens, thus more sensitive and speciﬁc
recombinant T. pallidum antigens would be useful for screening
syphilis patients.
In this study, Tp0663, a 28-kDa T. pallidum subsp. pallidum outer
membrane protein that has surface-exposed epitopes,25 was
expressed as a recombinant version in E. coli; this may allow
the protein to be produced economically and in large quantities inTable 3
Comparison of the two syphilis serodiagnosis tests and clinical diagnosis
Serodiagnosis
test and result
Clinical diagnosis
(gold standard)
Sensitivity, %
(95% CI)
Speciﬁcity,
% (95% CI)
Positive Negative
ARCHITECT Syphilis TP
Positive 249 12 97.27
(94.46–98.67)
99.61
(99.32–99.78)
Negative 7 3058
Tp0663-based ELISA
Positive 253 0 98.83
(96.61–99.60)
100
(99.88–100)
Negative 3 3070
CI, conﬁdence interval.vitro due to the inherent advantage in the preparation of
recombinant antigen compared to the extraction of crude T.
pallidum antigen.22 The molecular weight of the expressed
recombinant protein was a little larger than that predicted,
possibly due to the His tag at the N terminus. Consistent with the
works performed by McKevitt et al.10 and Brinkman et al.,11 the
recombinant protein identiﬁed by SDS-PAGE was found to be
reactive with sera from rabbits infected with the T. pallidum
Nichols strain and with sera from syphilis patients. However, no
reactivity was observed between recombinant protein Tp0663 and
uninfected controls and potentially cross-reactive serum samples,
showing the recombinant antigen to be a highly sensitive and
speciﬁc candidate for the serodiagnosis of syphilis in Western
blotting analysis.
The direct comparison of the diagnostic performances of the
recombinant T. pallidum antigen Tp0663 and the ARCHITECT
Syphilis TP tests is one focus of this study. Using the clinical
diagnostic results as the gold standard, the ARCHITECT Syphilis TP
exhibited a sensitivity of 97.27% and a speciﬁcity of 99.61%, while
Tp0663 showed a stronger discriminatory power for the sero-
diagnosis of syphilis (98.83% sensitivity and 100% speciﬁcity). Most
surveillance has focused on early syphilis cases, which is the best
indicator of the infection and more likely to result in the timely
treatment of patients. Thus, the serodiagnosis by the two
serological tests was further analyzed at the different stages of
syphilis, and especially in early syphilis. It was found that Tp0663Table 5
Direct comparison of the concordance between clinical diagnosis and the
Treponema pallidum recombinant antigen Tp0663-based ELISA or the ARCHITECT
Syphilis TP
Assay and result Clinical diagnosis
(gold standard)
Agreement %
(95% CI)
k value
Positive Negative Total
Tp0663-based ELISA
Positive 253 0 253 99.91 (99.88–99.94) 0.99
Negative 3 3070 3073
Total 256 3070 3326
ARCHITECT Syphilis TP
Positive 249 12 261 99.43 (99.36–99.50) 0.96
Negative 7 3058 3065
Total 256 3070 3326
CI, conﬁdence interval.
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Syphilis TP, although both tests showed high diagnostic signiﬁ-
cance in early syphilis, as well as in late syphilis. In particular,
12 false-positives would have resulted from the screening of all of
the serum samples with the ARCHITECT Syphilis TP. This may be
explained by the fact that the ELISA uses outer membrane protein
Tp0663 as an antigen, which is thought to be exposed continuously
to the immune system and to continually stimulate robust
antibody responses, thus having a theoretical advantage in the
detection of speciﬁc antibodies in individuals with syphilis.25 In
contrast, the ARCHITECT Syphilis TP uses lipoproteins TpN15,
TpN17, and TpN47 as the coated antigens; these are thought to be
able to induce a strong immune response by activating antigen-
presenting cells through toll-like receptor 2.26,27 Some of these
lipoprotein antigens are believed to be concealed in the periplasm
of the bacterium,28 although they were at ﬁrst considered to reside
on the surface of this pathogen. Moreover, the high overall
percentage of agreement and corresponding k values found in this
study indicated that the ELISA was in perfect agreement with
clinical diagnosis. Based on these results, recombinant antigen
Tp0663 may represent an effective candidate for the seroscreening
of syphilis.
It should be emphasized that Tp0663 may be compatible with
commercially available diagnostic tests, such as CIAs and EIAs,
since the protein is expressed in a soluble form. Currently, most
automated tests used for the serodiagnosis of syphilis utilize
multiple recombinant treponemal antigens. This has the potential
to confound results because patients may have different serologi-
cal responses to these antigens regardless of the presence of
infection.29 In addition, the development of a test using a single
recombinant treponemal protein could cut the costs associated
with the preparation of multiple antigens. Furthermore, Tp0663
does show the potential for detecting syphilis patients with high
accuracy, which may eliminate the need to perform a variety of
tests and thus decrease the medical burden for the patient. In
summary, these results suggest that Tp0663 is a promising
candidate for incorporation into many test formats for the
detection of syphilis.
A limitation of this study is that it was performed in a distinct
geographical location. The subjects tested were all recruited in
Hunan, China, which is an area with a relatively high prevalence of
syphilis, and samples were not collected from other areas with a
lower prevalence. Thus, this study only reﬂects the characteristics
of areas with a high prevalence of syphilis. Similar studies in lower-
prevalence regions will be performed in the future. Another
limitation is the potential misclassiﬁcation of patients due to the
possible incorrect documentation and inadequate documentation
in the medical records. Some patients used false information to
protect their privacy (including name, age, history of infection, and
inappropriate treatment they had received), which made it
difﬁcult to diagnose their syphilis infection and give them timely
and effective treatment.
In conclusion, a new serodiagnostic candidate – Tp0663 – has
been identiﬁed, which is extremely sensitive (98.83%) and speciﬁc
(100%) for the detection of all stages of the infection. In a direct
comparison, the serodiagnostic performance of the recombinant
protein even exceeded that of the commercially available
ARCHITECT Syphilis TP. Therefore, recombinant antigen Tp0663
may represent a new candidate for the detection of syphilis,
considering the potential for automation, high throughput, and its
valuable diagnostic performance.
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